TrialClinical and translational science2022

A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab.

Andrew McKenzie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.